Symbols

AKBA

Akebia Therapeutics·NASDAQ

--(--)

AKBA fundamentals

AKBA Q4 2025 Earnings

Akebia Therapeutics (AKBA) released its earnings on Feb 26, 2026: revenue was 57.62M (YoY +23.92%), beat estimates; EPS was -0.05 (YoY +50.00%), missed estimates.

Revenue / YoY

57.62M

+23.92%

EPS / YoY

-0.05

+50.00%

Report date

Feb 26, 2026

AKBA Earnings Call Summary for Q4,2025

Vafseo Momentum: 2025 net revenue of $45.8 million, with Q4 demand stabilizing at $11 million amid adherence challenges.
Adherence Improvement: Q1 2026 first refill rate of 87% (vs. 75% in 2025) for observed dosing patients.
Pipeline Expansion: Rare kidney disease assets (praliciguat, AKB-097, AKB-9090) advancing into Phase II/III trials.
Financial Strength: $184.8 million cash balance, with Auryxia revenue expected to decline in 2026 due to generics.

Earnings

EPS

Revenue

Revenue & Expenses

AKBA has released its 2025 Q4 earnings report, with revenue of 57.62M, reflecting a YoY change of 23.93%, and net profit of -12.24M, showing a YoY change of 46.31%. The Sankey diagram below clearly presents AKBA's revenue sources and cost distribution.

Key Indicators

Akebia Therapeutics (AKBA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Akebia Therapeutics (AKBA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Akebia Therapeutics (AKBA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Akebia Therapeutics (AKBA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown